What's Happening?
AI technology is revolutionizing the feasibility and site selection process in clinical trials. Traditionally, these processes have been manual and assumption-based, often leading to delays and budget overruns. However, AI-driven approaches are transforming
this by connecting protocol requirements with historical trial performance and real-world treatment patterns. This allows sponsors to identify higher-potential sites, improve enrollment predictability, and accelerate study startup timelines. The integration of AI reduces the feasibility process from months to weeks, enabling faster market entry for new therapeutics. AI models analyze historical studies and operational trends to identify eligibility criteria that may limit recruitment, thus improving trial cost and speed.
Why It's Important?
The adoption of AI in clinical trials is significant as it addresses major challenges such as recruitment difficulties and costly amendments. By improving site selection and enrollment forecasting, AI helps reduce inefficiencies that impact trial costs and timelines. This is crucial as clinical trials become more global and complex. For sponsors, AI-driven feasibility enables proactive decision-making, reducing downstream inefficiencies. For trial sites, it eliminates repetitive surveys and enhances engagement with sponsors. Overall, AI's role in clinical trials is pivotal in bringing therapies to patients more efficiently and with greater precision.
What's Next?
As AI adoption accelerates, organizations that embrace AI-enabled feasibility and protocol optimization will be better positioned to launch studies faster and reduce costly delays. The future of feasibility is moving towards a predictive, evidence-driven approach that improves enrollment confidence and startup efficiency. This shift is expected to continue reshaping the clinical development lifecycle, allowing sponsors to make more informed decisions and improve trial outcomes.
